Company Overview - Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, OhtuvayreTM (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Upcoming Financial Results - Verona Pharma will report its financial results for the first quarter ended March 31, 2025, on April 29, 2025 [1] - An investment community conference call will be hosted at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update [1] - A live webcast will be available on the company's website, and an audio replay will be accessible for 90 days [1]

Core Insights - The article emphasizes the importance of conducting independent research before making investment decisions, highlighting the inherent volatility and risks associated with stock investments [2][3]. Group 1 - The content is intended to provide informational insights rather than exhaustive analysis of any featured company [2]. - The predictions and opinions presented are based on a probabilistic approach, indicating that they do not guarantee absolute certainty [2]. - Readers are encouraged to verify the information independently and assess their financial circumstances before investing [2]. Group 2 - The article clarifies that past performance is not indicative of future results, underscoring the speculative nature of investments [3]. - It notes that the views expressed may not reflect those of the broader platform, indicating a diversity of opinions among analysts [3]. - The authors of the article include both professional and individual investors, some of whom may not be licensed or certified [3].

Core Viewpoint - Verona Pharma has successfully amended its strategic financing agreements, repaying the RIPSA and increasing its term loan facility to $450 million with improved terms, enhancing financial flexibility and simplifying its balance sheet [3][4]. Financing Agreements - The company repurchased the $100 million obligation under the RIPSA with reduced repayment fees [5]. - The term loan facility was increased to $450 million, with $125 million borrowed from an expanded Tranche C, resulting in an aggregate of $250 million outstanding [8]. - The interest rate on the term loan was reduced from 11% to 9.7%, with a further reduction to 9.35% upon achieving certain sales milestones [8]. - A provision was added allowing Verona Pharma to secure a working capital revolving credit facility of up to $75 million with a separate group [8]. Product Development - The ongoing success of the Ohtuvayre™ (ensifentrine) launch has been recognized, contributing to the growth of prescriptions and enabling the termination of the RIPSA [4]. - Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities [8]. - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [9]. Partnerships - Oaktree Capital Management and OMERS Life Sciences are key partners in the financing arrangements, expressing confidence in the US launch of Ohtuvayre and the company's growth prospects [4][10].

Financial Data and Key Metrics Changes - In Q4 2024, net sales of O2VARE were $36.6 million, and for the full year 2024, net sales were $42.3 million [5][14] - Research and development costs increased to $7.9 million in Q4 2024 from $4.1 million in Q4 2023, and for the full year, they rose to $44.6 million from $17.2 million in 2023 [16] - Selling, general, and administrative expenses were $45.1 million for Q4 2024, compared to $15 million in Q4 2023, and for the full year, they increased to $149.8 million from $50.4 million in 2023 [17] - The net loss after tax was $33.8 million for Q4 2024, compared to a loss of $14.1 million in Q4 2023, and for the full year, the loss was $173.4 million compared to $54.4 million in 2023 [17][18] - The company reported a strong balance sheet with $400 million in cash and equivalents as of December 31, 2024 [18] Business Line Data and Key Metrics Changes - The launch of O2VARE has shown strong initial metrics, with more prescriptions dispensed in the first two months of Q1 2025 than in Q4 2024 [6] - Over 4,600 unique healthcare providers (HCPs) are prescribing O2VARE, with approximately 55% of targeted tier one HCPs participating [7] - The product is being prescribed across a broad range of COPD patients, including those on single, dual, and triple therapy [8] Market Data and Key Metrics Changes - O2VARE received FDA approval and was launched in the US, marking a significant advancement in COPD treatment options [4] - The product has also been approved in Macau for the maintenance treatment of COPD, indicating expansion into international markets [12] Company Strategy and Development Direction - The company aims to continue expanding its prescriber base and is optimistic about the potential of O2VARE to become a blockbuster product [6][9] - Verona Pharma is preparing for potential marketing authorization applications in the European Union and the UK, while also advancing regulatory processes [12][44] - The company is focused on executing its global strategy and enhancing its pipeline with ongoing clinical trials [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the unmet need for COPD treatments and the ongoing momentum of O2VARE's launch [37][40] - There are no significant headwinds anticipated in the market, and competition is not seen as a threat in the foreseeable future [41] - The company is optimistic about the trajectory of O2VARE and the potential for cash flow breakeven by the end of 2025 [28][30] Other Important Information - The company has initiated activities with regulatory authorities in preparation for marketing authorization applications in Europe [12] - The feedback from patients and healthcare providers regarding O2VARE has been very positive, supporting its long-term potential [9][102] Q&A Session Summary Question: Volume trends and pricing impact on sales - Management discussed the potential impact of insurance resets on sales but indicated that the momentum of the launch would likely outweigh these effects [21][25] Question: 2025 consensus and breakeven expectations - Management believes that cash flow breakeven could be achieved at an annual run rate of $250 to $300 million by the end of 2025 [28][30] Question: Headwinds and risks - Management acknowledged the importance of execution in the pharmaceutical business but remains optimistic about the market dynamics and unmet needs [37][42] Question: Duration of therapy and average revenue per patient - Management indicated that there is potential upside to the average duration of therapy, which is currently modeled at six refills per year [49][52] Question: Prescriber dynamics and nebulizer usage - Management noted that the adoption of O2VARE is typical of early and late adopters, and the route of administration has not been a significant barrier [60][63] Question: Reimbursement rates and strategies - Management reported that approximately 80% of reimbursement claims fall under a medical benefit, and they are pleased with the access and reimbursement dynamics [86][90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission file number: 001-38067 Verona Pharma plc (Exact Name of Registrant as Specified in Its Charter) United Kingdom 98-1489389 (State or Other ...

Financial Performance - The company anticipates net product sales of approximately $36 million for the fourth quarter ended December 31, 2024[6]. - As of December 31, 2024, Verona Pharma plc expects to report approximately $400 million in cash and cash equivalents[6]. Preliminary Results - These preliminary financial results are based on unaudited information and are subject to change[7]. - The independent registered public accounting firm has not conducted an audit or review of these preliminary estimates[7]. - The press release regarding these results was issued on January 7, 2025[9].

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or ...

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA Leerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL A webcast of each ...

LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting Verona Pharma PLC (VRNA) as a strong candidate for trend investing due to its recent performance and positive fundamentals [1][3]. Price Performance - VRNA has experienced a significant price increase of 55.8% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - In the last four weeks, VRNA's price has risen by 22.5%, suggesting that the upward trend is still intact [5]. - Currently, VRNA is trading at 94.7% of its 52-week high-low range, indicating it may be on the verge of a breakout [5]. Fundamental Strength - VRNA holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [7]. Additional Insights - The article suggests that VRNA is likely to maintain its price trend, and encourages investors to explore other stocks that meet the "Recent Price Strength" criteria [8]. - It also mentions the availability of over 45 Zacks Premium Screens to assist investors in identifying potential winning stocks based on their investing style [8].